GAITHERSBURG, Md. -- MedImmune, Inc. announced today that data from a preclinical study for its lead vaccine candidate to prevent respiratory syncytial virus (RSV) and parainfluenza virus type-3 (PIV-3) has shown a protective immune response against both viruses in animals. The results of the study, published in the October 2004 issue of the Journal of Virology, support the continued development of vaccine candidates to prevent these two leading causes of respiratory illness in young children. The data also serve as a platform for the development of other vaccines to protect infants from various respiratory infections. MedImmune is planning to file an investigative new drug application (IND) to begin clinical testing of a RSV/PIV-3 vaccine candidate as soon as the end of 2004.
According to the study, RSV-neutralizing antibodies were identified in African Green Monkeys following administration of a bivalent vaccine for RSV and PIV-3.
"We are encouraged by the results of the preclinical study and are hopeful that we will continue to receive positive data from our ongoing research with our PIV-3/RSV vaccine candidate," said Richard Spaete, Ph.D., senior research director at MedImmune. "Such results take us one step closer to developing vaccines that have the potential to prevent these serious pediatric respiratory viruses as well as others such as human metapneumovirus."
RSV, PIV-3 and hMPV are viruses that cause serious respiratory disease, particularly in young children, the elderly, and immunocompromised individuals. RSV is the most common cause of lower respiratory tract infections in infants and children worldwide, typically occurring during the fall and winter months. PIV-3 is the leading cause of croup, an acute lower respiratory disease most often observed in young children. A recently identified virus, hMPV is believed to cause serious lower respiratory tract infections in young children.
The study published in the Journal of Virology is entitled "Parainfluenza Virus Type-3 Expressing the Native or Soluble Fusion (F) Protein of Respiratory Syncytial Virus (RSV) Confers Protection from RSV Infection in African Green Monkeys."
MedImmune has recently published additional studies in support of its pediatric respiratory vaccine platform. A study published in a June 2004 issue of the Journal of General Virology showed that hamsters, ferrets and African Green Monkeys supported hMPV replication efficiently and produced high levels of hMPV-neutralizing antibodies. In a study in an August 2004 issue of Journal of Virology, researchers announced recovery of cloned hMPV, a technique which provides the potential to generate vaccines that may eventually be useful in preventing hMPV infection.
Source: MedImmune, Inc.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.